{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-218162","form_type":"8-K","ticker":"PRLD","cik":"0001678660","company_name":"Prelude Therapeutics Inc","filed_at":"2026-05-12T11:11:58+00:00","discovered_at":"2026-05-12T11:15:00.267422+00:00","generated_at":"2026-05-12T11:16:46.660311+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Prelude Therapeutics Q1 net loss $10.4M ($0.13/sh); cash runway into Q2 2028 after $90M offering","bullets":["Net loss of $10.4M ($0.13 per share) vs $32.1M ($0.42) in Q1 2025; R&D spend fell to $13.6M.","Cash, equivalents & securities of $84.8M at March 31; subsequent $90M offering extends runway to Q2 2028.","Initiated Phase 1 trial of PRT12396, mutant-selective JAK2V617F inhibitor, in PV and MF patients.","IND for KAT6A degrader PRT13722 expected by mid-2026; Phase 1 in ER+ breast cancer in 2H 2026.","Appointed Charles Morris, M.D. as Chief Medical Officer in April 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-218162","json":"https://secwatch.observer/filing/0001193125-26-218162.json","markdown":"https://secwatch.observer/filing/0001193125-26-218162.md","text":"https://secwatch.observer/filing/0001193125-26-218162.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1678660/000119312526218162/0001193125-26-218162-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1678660/000119312526218162/prld-20260512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T11:16:46.660311+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c6f625ba4fbf0534e41c5907cbe3c48869703f1b","claim":"Prelude Therapeutics Inc reported financial results for the three months ended March 31, 2026.","evidence_excerpt":"On May 12, 2026, Prelude Therapeutics Incorporated (the \"Company\") issued a press release announcing its financial results for the three months ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1678660/000119312526218162/0001193125-26-218162-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}